Marktanalyse - Hypertension - Pipeline Review, H2 2016

Global Markets Direct
12.2016
551 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Hypertension - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension — Pipeline Review, H2 2016, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 32, 28, 26, 85 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 8 molecules, respectively.

Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 7

Hypertension Overview 8

Therapeutics Development 9

Hypertension - Therapeutics under Development by Companies 11

Hypertension - Therapeutics under Investigation by Universities/Institutes 19

Hypertension - Pipeline Products Glance 21

Hypertension - Products under Development by Companies 24

Hypertension - Products under Investigation by Universities/Institutes 37

Hypertension - Companies Involved in Therapeutics Development 39

Hypertension - Therapeutics Assessment 146

Drug Profiles 168

Hypertension - Dormant Projects 486

Hypertension - Discontinued Products 512

Hypertension - Product Development Milestones 515

Appendix 527





List of Tables

Number of Products under Development for Hypertension, H2 2016 32

Number of Products under Development for Hypertension - Comparative Analysis, H2 2016 33

Number of Products under Development by Companies, H2 2016 34

Number of Products under Development by Companies, H2 2016 (Contd..1) 35

Number of Products under Development by Companies, H2 2016 (Contd..2) 36

Number of Products under Development by Companies, H2 2016 (Contd..3) 37

Number of Products under Development by Companies, H2 2016 (Contd..4) 38

Number of Products under Development by Companies, H2 2016 (Contd..5) 39

Number of Products under Development by Companies, H2 2016 (Contd..6) 40

Number of Products under Development by Companies, H2 2016 (Contd..7) 41

Number of Products under Investigation by Universities/Institutes, H2 2016 43

Comparative Analysis by Late Stage Development, H2 2016 44

Comparative Analysis by Clinical Stage Development, H2 2016 45

Comparative Analysis by Early Stage Development, H2 2016 46

Products under Development by Companies, H2 2016 47

Products under Development by Companies, H2 2016 (Contd..1) 48

Products under Development by Companies, H2 2016 (Contd..2) 49

Products under Development by Companies, H2 2016 (Contd..3) 50

Products under Development by Companies, H2 2016 (Contd..4) 51

Products under Development by Companies, H2 2016 (Contd..5) 52

Products under Development by Companies, H2 2016 (Contd..6) 53

Products under Development by Companies, H2 2016 (Contd..7) 54

Products under Development by Companies, H2 2016 (Contd..8) 55

Products under Development by Companies, H2 2016 (Contd..9) 56

Products under Development by Companies, H2 2016 (Contd..10) 57

Products under Development by Companies, H2 2016 (Contd..11) 58

Products under Development by Companies, H2 2016 (Contd..12) 59

Products under Investigation by Universities/Institutes, H2 2016 60

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 61

Hypertension - Pipeline by A1M Pharma AB, H2 2016 62

Hypertension - Pipeline by AbbVie Inc, H2 2016 63

Hypertension - Pipeline by Actelion Ltd, H2 2016 64

Hypertension - Pipeline by Afferent Pharmaceuticals Inc, H2 2016 65

Hypertension - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 66

Hypertension - Pipeline by Anacor Pharmaceuticals Inc, H2 2016 67

Hypertension - Pipeline by AnGes MG Inc, H2 2016 68

Hypertension - Pipeline by APT Therapeutics Inc, H2 2016 69

Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2 2016 70

Hypertension - Pipeline by Ascendis Pharma A/S, H2 2016 71

Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H2 2016 72

Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 73

Hypertension - Pipeline by Bayer AG, H2 2016 74

Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2016 75

Hypertension - Pipeline by Biolab Farmaceutica Ltda, H2 2016 76

Hypertension - Pipeline by BioRestorative Therapies Inc, H2 2016 77

Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 78

Hypertension - Pipeline by Cellceutix Corp, H2 2016 79

Hypertension - Pipeline by Celsion Corp, H2 2016 80

Hypertension - Pipeline by Celtaxsys Inc, H2 2016 81

Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 82

Hypertension - Pipeline by CJ HealthCare Corp, H2 2016 83

Hypertension - Pipeline by Complexa Inc, H2 2016 84

Hypertension - Pipeline by Conatus Pharmaceuticals Inc, H2 2016 85

Hypertension - Pipeline by Corion Biotech Srl, H2 2016 86

Hypertension - Pipeline by Cumberland Pharmaceuticals Inc, H2 2016 87

Hypertension - Pipeline by Cytokinetics Inc, H2 2016 88

Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 89

Hypertension - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 90

Hypertension - Pipeline by DiaMedica Inc, H2 2016 91

Hypertension - Pipeline by Eli Lilly and Company, H2 2016 92

Hypertension - Pipeline by Esperion Therapeutics Inc, H2 2016 93

Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 94

Hypertension - Pipeline by Ferring International Center SA, H2 2016 95

Hypertension - Pipeline by Galectin Therapeutics Inc, H2 2016 96

Hypertension - Pipeline by Genextra Spa, H2 2016 97

Hypertension - Pipeline by Gilead Sciences Inc, H2 2016 98

Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2016 99

Hypertension - Pipeline by Glenveigh Medical LLC, H2 2016 100

Hypertension - Pipeline by HanAll Biopharma Co Ltd, H2 2016 101

Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 102

Hypertension - Pipeline by HitGen LTD, H2 2016 103

Hypertension - Pipeline by Innopharmax Inc, H2 2016 104

Hypertension - Pipeline by Insmed Inc, H2 2016 105

Hypertension - Pipeline by INVENT Pharmaceuticals Inc, H2 2016 106

Hypertension - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 107

Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H2 2016 108

Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 109

Hypertension - Pipeline by Johnson & Johnson, H2 2016 110

Hypertension - Pipeline by JW Pharmaceutical Corp, H2 2016 111

Hypertension - Pipeline by Kowa Company Ltd, H2 2016 112

Hypertension - Pipeline by Leading BioSciences Inc, H2 2016 113

Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2016 114

Hypertension - Pipeline by Les Laboratoires Servier SAS, H2 2016 115

Hypertension - Pipeline by LFB SA, H2 2016 116

Hypertension - Pipeline by LG Life Science LTD, H2 2016 117

Hypertension - Pipeline by LinXis BV, H2 2016 118

Hypertension - Pipeline by Liquidia Technologies Inc, H2 2016 119

Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016 120

Hypertension - Pipeline by MannKind Corp, H2 2016 121

Hypertension - Pipeline by Mast Therapeutics Inc, H2 2016 122

Hypertension - Pipeline by Merck & Co Inc, H2 2016 123

Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2016 124

Hypertension - Pipeline by miRagen Therapeutics Inc, H2 2016 125

Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 126

Hypertension - Pipeline by Morphogen-IX Ltd, H2 2016 127

Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 128

Hypertension - Pipeline by Nippon Kayaku Co Ltd, H2 2016 129

Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2016 130

Hypertension - Pipeline by Novartis AG, H2 2016 131

Hypertension - Pipeline by Noxamet Ltd, H2 2016 132

Hypertension - Pipeline by Omeros Corp, H2 2016 133

Hypertension - Pipeline by Peloton Therapeutics Inc, H2 2016 134

Hypertension - Pipeline by Pfizer Inc, H2 2016 135

Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016 136

Hypertension - Pipeline by Pluristem Therapeutics Inc, H2 2016 137

Hypertension - Pipeline by Polyphor Ltd, H2 2016 138

Hypertension - Pipeline by Proteo Inc, H2 2016 139

Hypertension - Pipeline by Pulmokine Inc, H2 2016 140

Hypertension - Pipeline by Quantum Genomics SA, H2 2016 141

Hypertension - Pipeline by Reata Pharmaceuticals Inc, H2 2016 142

Hypertension - Pipeline by RedHill Biopharma Ltd, H2 2016 143

Hypertension - Pipeline by Respira Therapeutics Inc, H2 2016 144

Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H2 2016 145

Hypertension - Pipeline by Sanofi, H2 2016 146

Hypertension - Pipeline by Selten Pharma Inc, H2 2016 147

Hypertension - Pipeline by Serodus ASA, H2 2016 148

Hypertension - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016 149

Hypertension - Pipeline by Silence Therapeutics Plc, H2 2016 150

Hypertension - Pipeline by Simcere Pharmaceutical Group, H2 2016 151

Hypertension - Pipeline by SteadyMed Therapeutics Inc, H2 2016 152

Hypertension - Pipeline by Suda Ltd, H2 2016 153

Hypertension - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 154

Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 155

Hypertension - Pipeline by The Medicines Company, H2 2016 156

Hypertension - Pipeline by Theravance Biopharma Inc, H2 2016 157

Hypertension - Pipeline by Toray Industries Inc, H2 2016 158

Hypertension - Pipeline by Torrent Pharmaceuticals Ltd, H2 2016 159

Hypertension - Pipeline by TSH Biopharm Corporation Ltd, H2 2016 160

Hypertension - Pipeline by United Therapeutics Corp, H2 2016 161

Hypertension - Pipeline by VBS Pharmaceuticals, H2 2016 162

Hypertension - Pipeline by Vectura Group Plc, H2 2016 163

Hypertension - Pipeline by VG Life Sciences Inc, H2 2016 164

Hypertension - Pipeline by Vicore Pharma AB, H2 2016 165

Hypertension - Pipeline by XORTX Pharma Corp, H2 2016 166

Hypertension - Pipeline by XuanZhu Pharma Co Ltd, H2 2016 167

Hypertension - Pipeline by Yuhan Corp, H2 2016 168

Assessment by Monotherapy Products, H2 2016 169

Assessment by Combination Products, H2 2016 170

Number of Products by Stage and Target, H2 2016 172

Number of Products by Stage and Mechanism of Action, H2 2016 180

Number of Products by Stage and Route of Administration, H2 2016 188

Number of Products by Stage and Molecule Type, H2 2016 190

Hypertension - Dormant Projects, H2 2016 509

Hypertension - Dormant Projects (Contd..1), H2 2016 510

Hypertension - Dormant Projects (Contd..2), H2 2016 511

Hypertension - Dormant Projects (Contd..3), H2 2016 512

Hypertension - Dormant Projects (Contd..4), H2 2016 513

Hypertension - Dormant Projects (Contd..5), H2 2016 514

Hypertension - Dormant Projects (Contd..6), H2 2016 515

Hypertension - Dormant Projects (Contd..7), H2 2016 516

Hypertension - Dormant Projects (Contd..8), H2 2016 517

Hypertension - Dormant Projects (Contd..9), H2 2016 518

Hypertension - Dormant Projects (Contd..10), H2 2016 519

Hypertension - Dormant Projects (Contd..11), H2 2016 520

Hypertension - Dormant Projects (Contd..12), H2 2016 521

Hypertension - Dormant Projects (Contd..13), H2 2016 522

Hypertension - Dormant Projects (Contd..14), H2 2016 523

Hypertension - Dormant Projects (Contd..15), H2 2016 524

Hypertension - Dormant Projects (Contd..16), H2 2016 525

Hypertension - Dormant Projects (Contd..17), H2 2016 526

Hypertension - Dormant Projects (Contd..18), H2 2016 527

Hypertension - Dormant Projects (Contd..19), H2 2016 528

Hypertension - Dormant Projects (Contd..20), H2 2016 529

Hypertension - Dormant Projects (Contd..21), H2 2016 530

Hypertension - Dormant Projects (Contd..22), H2 2016 531

Hypertension - Dormant Projects (Contd..23), H2 2016 532

Hypertension - Dormant Projects (Contd..24), H2 2016 533

Hypertension - Dormant Projects (Contd..25), H2 2016 534

Hypertension - Discontinued Products, H2 2016 535

Hypertension - Discontinued Products (Contd..1), H2 2016 536

Hypertension - Discontinued Products (Contd..2), H2 2016 537





List of Figures

Number of Products under Development for Hypertension, H2 2016 32

Number of Products under Development for Hypertension - Comparative Analysis, H2 2016 33

Number of Products under Development by Companies, H2 2016 34

Number of Products under Investigation by Universities/Institutes, H2 2016 42

Comparative Analysis by Late Stage Development, H2 2016 44

Comparative Analysis by Clinical Stage Development, H2 2016 45

Comparative Analysis by Early Stage Products, H2 2016 46

Assessment by Monotherapy Products, H2 2016 169

Assessment by Combination Products, H2 2016 170

Number of Products by Top 10 Targets, H2 2016 171

Number of Products by Stage and Top 10 Targets, H2 2016 171

Number of Products by Top 10 Mechanism of Actions, H2 2016 179

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 179

Number of Products by Top 10 Routes of Administration, H2 2016 187

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 187

Number of Products by Top 10 Molecule Types, H2 2016 189

Number of Products by Stage and Top 10 Molecule Types, H2 2016 189

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus